durvalumab
astrazeneca
['nsclc', 'check,mate,017', 'sclc', 'check,mate,004', 'optima', 'check,mate,003', 'advanced i', 'optimum', 'check,mate,038', 'gamma', 'flex', 'check,mate,037', 'waves', 'check,mate,025', 'pacific,(-pacifica),(-pacific 6),(-pacific6),(-pacific-6),(-pacific-a),(-pacific a)', 'spare', 'surpass', 'core i', 'check,mate,064', 'oreo', 'biomarker', 'check,mate,002', 'dance', 'orien', 'durva', 'genesis,(-pathogenesis)', 'selection,(-selectionlte),(-selection lte),(-selection-lte)', 'lung', 'immune therap', 'cleveland ', 'marker ']
enjoyed hearing from about the pacific-r study interim analysis at #esmoimmuno22. read how novel imaging biomarkers predict outcomes in stage iii unresectable nsclc treated with chemoradiation and durvalumab in #jitc from et al. 
#JITC is the official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. Editor-in-Chief: Pedro J. Romero, MD.